Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
DNA · against 1,335 other Healthcare companies
Ranked #1,156 of 1,336 · scores higher than 13% of peers
Bars: peers in each 10-point band of the profitability score134 peers with a profitability score of 10–19, including DNA · Click a bar to see the companies
Mainly because of its return on invested capital and operating margin, which are weaker than most Healthcare peers.
| Metric | DNA | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Return on invested capitalHigher is better · 1,226 reported | -72.0% | 4.7% | 9% | 33% | |
| Operating marginHigher is better · 1,251 reported | -231.1% | 7.1% | 10% | 33% | |
| Return on assetsHigher is better · 1,315 reported | 2.2% | 1.7% | 55% | 33% | |
| Return on equityHigher is better · 1,252 reported | -59.9% | 3.2% | 12% | Context only | |
| Gross marginHigher is better · 1,394 reported | 68.0% | 45.9% | 75% | Context only |
| Rank | Company | Market cap | Profitability | Overall |
|---|---|---|---|---|
| 1 | 3.1B EUR (≈$3.4B) | 100 | 100 | |
| 1 | 321.5B INR (≈$3.9B) | 100 | 70 | |
| 1 | 174.8B INR (≈$2.1B) | 100 | 73 | |
| 1 | 97.3B INR (≈$1.2B) | 100 | 80 | |
| 5 | 12.3B CNY (≈$1.7B) | 99 | 85 | |
| 1,143 | 2.3B USD | 14 | 27 | |
| 1,156 | 198M USD | 13 | 10 | |
| 1,156 | 3.7B USD | 13 | 31 | |
| 1,156 | 968M USD | 13 | 37 | |
| 1,156 | 725M USD | 13 | 19 | |
| 1,156 | 1.4B USD | 13 | 38 | |
| 1,156 | 1.2B CHF (≈$1.3B) | 13 | 28 | |
| 1,156 | 5.7B USD | 13 | 30 | |
| 1,156 | 27M USD | 13 | 24 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score